SCHEMBL13633862

SCHEMBL13633862

COc1ccc(NS(=O)(=O)c2ccc(-c3cnco3)s2)c2ncccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 4/20 0.53
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
AGTR1 P30556 1/20 0.51
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SLC40A1 Q9NP59 3/20 0.46
TP53 P04637 2/20 0.45
PFKFB3 Q16875 1/20 0.43
CKS1B P61024 3/20 0.42
SKP2 Q13309 3/20 0.42
GLO1 Q04760 1/20 0.42
HTT P42858 2/20 0.41
S1PR4 O95977 1/20 0.41
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
S1PR1 P21453 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13633860 0.85 SLC40A1 (0.54) GHSRMEN1KMT2ASLC40A1TP53
SCHEMBL13633914 0.81 SLC40A1 (0.61) MEN1KMT2AAGTR1SLC40A1PFKFB3
SCHEMBL13633847 0.78 GABRA1 (0.55) GHSRMEN1KMT2AAGTR1SLC40A1
SCHEMBL1591490 0.74 AXL (0.62) GHSR
SCHEMBL27214214 0.73 MEN1 (0.60) MEN1KMT2AAGTR1SLC40A1CKS1B
SCHEMBL30925531 0.70 SLC40A1 (0.64) MEN1KMT2AAGTR1SLC40A1CKS1B
SCHEMBL29255660 0.70 ALDH1A1 (0.72) GHSRMEN1KMT2AAGTR1SLC40A1
SCHEMBL30854824 0.70 ALDH1A1 (0.72) GHSRMEN1KMT2AAGTR1SLC40A1
SCHEMBL4804560 0.70 GHSR (1.00) GHSR
SCHEMBL4804541 0.70 GHSR (1.00) GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-8470821-B2 PDE4B inhibitors and uses therefor PLEXXIKON INC. (US) 2013-06-25 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PLEXXIKON, INC. 2009-11-19 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed
US-7585859-B2 PDE4B inhibitors and uses therefor PLEXXIKON, INC. (US) 2009-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286793-A1 PDE4B INHIBITORS AND USES THEREFOR PDE4B, PDE7B, PDE4A GHSR 2722/4885MEN1 2737/4885KMT2A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.